Pharmaceutical compositions that include an amount of an acid addition salt of pazopanib equivalent to about 5 mg/mL pazopanib, about 2.0 to about 13.0% w/w of a modified cyclodextrin suitable for use in an ophthalmic formulation, and pH adjusting agent as well as methods of making the same are described.